Neurocrine Biosciences | NBIX - Ebit


Neurocrine Biosciences reported $343M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.61B 777M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Exelixis USD 268.42M 20.01M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pfizer USD -180M 5.16B Jun/2026
Prothena USD -18.69M 44.48M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Repligen USD 24.31M 3.18M Sep/2026
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026